Abstract

Background

Antibiotic resistance is a growing global health concern prompting researchers to seek alternatives to conventional antibiotics. Antimicrobial peptides (AMPs) are attracting attention again as therapeutic agents with promising utility in this domain, and using in silico methods to discover novel AMPs is a strategy that is gaining interest. Such methods can sift through large volumes of candidate sequences and reduce lab screening costs.

Results

Here we introduce AMPlify, an attentive deep learning model for AMP prediction, and demonstrate its utility in prioritizing peptide sequences derived from the Rana [Lithobates] catesbeiana (bullfrog) genome. We tested the bioactivity of our predicted peptides against a panel of bacterial species, including representatives from the World Health Organization’s priority pathogens list. Four of our novel AMPs were active against multiple species of bacteria, including a multi-drug resistant isolate of carbapenemase-producing Escherichia coli.

Conclusions

We demonstrate the utility of deep learning based tools like AMPlify in our fight against antibiotic resistance. We expect such tools to play a significant role in discovering novel candidates of peptide-based alternatives to classical antibiotics.

Details

Title
AMPlify: attentive deep learning model for discovery of novel antimicrobial peptides effective against WHO priority pathogens
Author
Li, Chenkai; Sutherland, Darcy; S. Austin Hammond; Chen, Yang; Figali Taho; Bergman, Lauren; Houston, Simon; Warren, René L; Wong, Titus; Hoang, Linda M N; Cameron, Caroline E; Helbing, Caren C; Inanc Birol  VIAFID ORCID Logo 
Pages
1-15
Section
Research article
Publication year
2022
Publication date
2022
Publisher
BioMed Central
e-ISSN
14712164
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2630505793
Copyright
© 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.